Menu
Search
|

Menu

Close
X

Astellas Pharma Inc 4503.T (Tokyo Stock Exchange)

1,444.00 JPY
+13.00 (+0.91%)
As of 2:00 AM EDT
Previous Close 1,431.00
Open 1,446.00
Volume 2,697,400
3m Avg Volume 5,590,572
Today’s High 1,448.50
Today’s Low 1,436.50
52 Week High 2,056.00
52 Week Low 1,356.00
Shares Outstanding (mil) 2,068.82
Market Capitalization (mil) 3,012,207.00
Forward P/E 15.71
Dividend (Yield %) 18.00 ( 2.34 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.36 Mean rating from 11 analysts

KEY STATS

Revenue (mm, JPY)
FY20
334,134
FY19
1,306,348
FY18
1,300,316
FY17
1,311,665
FY16
1,372,706
EPS (JPY)
FY20
31.004
FY19
114.623
FY18
80.931
FY17
103.443
FY16
89.554
*Note: Units in Millions of Yen
**Note: Units in Yen

KEY RATIOS

Price to Earnings (TTM)
vs sector
15.71
32.67
Price to Sales (TTM)
vs sector
2.32
7.91
Price to Book (MRQ)
vs sector
2.28
5.38
Price to Cash Flow (TTM)
vs sector
11.66
24.37
Total Debt to Equity (MRQ)
vs sector
2.86
14.55
LT Debt to Equity (MRQ)
vs sector
2.56
10.20
Return on Investment (TTM)
vs sector
13.91
14.48
Return on Equity (TTM)
vs sector
15.50
15.78

EXECUTIVE LEADERSHIP

Yoshihiko Hatanaka
Chairman of the Board, Chairman of the Board of Directors, Representative Director, Since 2018
Salary: --
Bonus: --
Kenji Yasukawa
President, Chief Executive Officer, Representative Director, Since 2018
Salary: --
Bonus: --
Nobuaki Tanaka
Senior Executive Officer, Chief Director of Sales, Since 2018
Salary: --
Bonus: --
Akihiko Iwai
Senior Executive Officer, Chief Director of Research, Since 2018
Salary: --
Bonus: --
Atsushi Kamide
Senior Executive Officer, Director of External Affairs, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2-5-1, Nihombashihon-cho
CHUO-KU   TKY   103-8411

Phone: +813.32443000

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. The Company also engages in the research and development of ophthalmology pharmaceuticals through its subsidiaries.

SPONSORED STORIES